[A clinical study of nonsquamous cell carcinoma of the nasal and paranasal sinuses].
We evaluated the efficacy of multimodality therapy for nonsquamous cell carcinoma (salivary carcinoma) of the nasal and paranasal sinuses. We retrospectively analyzed 28 patients with nonsquamous cell carcinoma of the nasal cavity and paranasal sinuses between 1972 and 2005. Primary sites were the maxillary sinus in 20 patients, ethmoidal sinus in 1, and the nasal cavity in 7. Pathology included adenocarcinoma in 5, mucoepidermoid carcinoma in 4, adenoid cystic carcinoma in 18, and adenosquamous carcinoma in 1. Five-year survival was 55% in all cases, 50% in the maxillary and ethmoidal sinuses, and 71% in the nasal cavity. Adenoid cystic carcinoma recurrence persisted over the five years following primary treatment and salvage after recurrence was 0%. Multimodality therapy decreased primary-site recurrence more than nonmultimodality therapy. Multimodality therapy thus appears useful in the primary treatment of nonsquamous cell carcinoma in the nasal cavity and paranasal sinuses.
Rikimaru
Fumihide
F
Division of Head Neck Surgery, National Hospital Organization Kyusyu Cancer Center, Fukuoka.
Tomita
Kichinobu
K
D000230:Adenocarcinoma / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010255:Paranasal Sinus Neoplasms / Q000628:therapy*; D012189:Retrospective Studies